Window shadow (in window selection mode) Mouse cursor, mouse clicks and keyboard presses Adjust export settings for saved compositionsĮasily share your GIFs by copy-pasting them or drag-and-dropping from the status bar directly into other apps, or use built-in Dropbox, Google Drive, and Imgur integrations.Ĭapture options control what Gifox records, they can be changed in the Capture tab of the Preferences window. Refine recorded and imported graphics using the built-in editor and re-export with adjustable per-composition compression settings. Support for folder and bulk-file imports Compatible with most video and image formats Import existing GIFs and effortlessly convert videos and image sequences by drag-and-dropping them onto the Gifox status bar icon. Record isolated window, even if it gets moved or obscured Record everything within a selected screen region Tiny foxy “Made with Gifox” watermarkĪrea and window selection modes control what's being recorded on the screen. To remove restrictions and support ongoing app development, it can be upgraded to the Pro version via an in-app purchase – a one-time payment without subscriptions. The Basic version includes all features of the Pro, but has a recording limit and adds a small watermark to exported GIFs – it's completely free with no trials, signups, ads, or hidden annoyances. Gifox comes in two versions: Basic and Pro. Batch video and image sequence conversion Animated instructions and bug reporting Molecular remissions were documented in two patients with mantle cell NHL.īased on the results of this pilot study, we conclude that the R-GIFOX regimen is feasible, tolerable, effective and able to mobilize peripheral stem cells in patients with relapsed and refractory aggressive NHL.Gifox is a beautifully designed and masterfully crafted app for creating and editing animated GIFs – the great alternative between static images and full-size videos. Failure-free survival was 79.6% at median follow-up of 6 months (range 2-12). Hematologic and extra-hematologic toxicity was tolerable. Effective CD34(+) cell mobilization was obtained in four of six eligible patients and two had ASCT. The overall response rate assessed after three courses of R-GIFOX was 77%, with seven complete responses and three partial responses. Thirteen patients completed at least three courses of therapy and were evaluable for response. The median number of R-GIFOX courses delivered was 4 (range 1-6). Patients had received a median of two previous treatment lines (range 1-4). Responses were evaluated by the integrated FDG-PET/IWC criteria after the third course and at the end of the entire program.įourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study. Treatment was given every 2 weeks with G-CSF support (5 microg/kg/day or 10 microg/kg/day at the end of the third course for stem cell mobilization). R-GIFOX consisted of rituximab (375 mg/m(2) on day 1), gemcitabine (1000 mg/m(2) on day 2), oxaliplatin (130 mg/m(2) on day 3) and ifosfamide (5 g/m(2) on day 3) as a 24-h single infusion in patients aged 65 years. Patients were scheduled to receive three courses of therapy followed by mobilization and ASCT or three more courses if ineligible for ASCT. We evaluated the clinical activity, toxicity and mobilizing capacity of a new salvage regimen, which combines gemcitabine and oxaliplatin with ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20(+) NHL. Since high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) can cure a proportion of such patients, provided that a substantial tumor shrinkage is achieved, the development of more effective and less toxic salvage regimens remains a major challenge. The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
0 Comments
Leave a Reply. |